Literature DB >> 28360695

Antipsychotic Use Pattern in People with Psychotic Disorder Living in Board and Care Facilities.

Etem Erdal Ersan1, Mustafa Yildiz2.   

Abstract

INTRODUCTION: The aim of this survey is to determine the pattern of antipsychotic drug use in patients with psychotic disorders, living in board and care facilities and to investigate the related factors.
METHODS: We evaluated the antipsychotic drug use pattern in outpatients with psychotic disorders according to DSM-IV, living in board and care facilities. Patients using polypharmacy at least one month were compared with patients using monotherapy in terms of clinical and demographic characteristics.
RESULTS: Antipsychotic polypharmacy (with two: 34%, with more than two: 28%) was identified in 62% of the patients. The most frequently prescribed combination was olanzapine+quetiapine (13%), the rate of first and second generation combination was 50%, the rate of second generation antipsychotic combination was 44%, and the rate of first generation anytipsychotic combination was 4% in the two antipsychotic drug combination group. The rate of clozapine use was 3%. Use of polypharmacy was associated with the diagnosis of schizophrenia and schizoaffective disorder, young age, suicidal behavior, multiple hospitalizations, clinical severity, and the need of anticholinergic drug.
CONCLUSION: The ratio of using more than two antipsychotic drug combination is high (28%) in psychotic patients living in board and care, and rate of clozapine use is low, which shows that clinical practice is inconsistent with the treatment guidelines recommendations. It appears that further education to rationale antipsychotic drug use in psychiatric practices is required.

Entities:  

Keywords:  Psychotic disorder; antipsychotics; board and care facility; monotherapy; outpatient; polypharmacy; schizophrenia

Year:  2015        PMID: 28360695      PMCID: PMC5353189          DOI: 10.5152/npa.2015.7419

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  24 in total

1.  Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region.

Authors:  Ellen M Weissman
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

Review 2.  Practice guideline for the treatment of patients with schizophrenia, second edition.

Authors:  Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

3.  Polypharmacy of schizophrenia.

Authors:  Peter Dussias; Amir H Kalali; Leslie Citrome
Journal:  Psychiatry (Edgmont)       Date:  2010-08

Review 4.  The evolution of antipsychotic switch and polypharmacy in natural practice--a longitudinal perspective.

Authors:  Chisa Tsutsumi; Hiroyuki Uchida; Takefumi Suzuki; Koichiro Watanabe; Hiroyoshi Takeuchi; Shinichiro Nakajima; Yoshie Kimura; Yuichiro Tsutsumi; Koichi Ishii; Yasushi Imasaka; Shitij Kapur
Journal:  Schizophr Res       Date:  2011-05-31       Impact factor: 4.939

5.  Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries.

Authors:  Corrado Barbui; Michela Nosè; Maria Angela Mazzi; Graham Thornicroft; Aart Schene; Thomas Becker; Jonathan Bindman; Morven Leese; Hedda Helm; Maarten Koeter; Stefan Weinmann; Michele Tansella
Journal:  Int Clin Psychopharmacol       Date:  2006-11       Impact factor: 1.659

6.  Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment.

Authors:  G Längle; T Steinert; P Weiser; W Schepp; S Jaeger; C Pfiffner; K Frasch; G W Eschweiler; T Messer; D Croissant; T Becker; R Kilian
Journal:  Acta Psychiatr Scand       Date:  2012-02-09       Impact factor: 6.392

7.  Multiple antipsychotic medication prescribing patterns.

Authors:  Jennifer E Schumacher; Eugene H Makela; Holly R Griffin
Journal:  Ann Pharmacother       Date:  2003 Jul-Aug       Impact factor: 3.154

8.  Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.

Authors:  Daeyoung Roh; Jhin-Goo Chang; Chan-Hyung Kim; Hyun-Sang Cho; Suk Kyoon An; Young-Chul Jung
Journal:  Aust N Z J Psychiatry       Date:  2013-05-13       Impact factor: 5.744

9.  [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].

Authors:  P Bret; M-C Bret; E Queuille
Journal:  Encephale       Date:  2008-07-07       Impact factor: 1.291

10.  The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

Authors:  Troy A Moore; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Susan M Essock; Molly Finnerty; Stephen R Marder; Del D Miller; Joseph P McEvoy; Delbert G Robinson; Nina R Schooler; Steven P Shon; T Scott Stroup; Alexander L Miller
Journal:  J Clin Psychiatry       Date:  2007-11       Impact factor: 4.384

View more
  1 in total

1.  Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy.

Authors:  Esra Yazici; Ali S Cilli; Ahmet B Yazici; Hayriye Baysan; Mustafa Ince; Sukriye Bosgelmez; Serkan Bilgic; Betul Aslan; Atila Erol
Journal:  Clin Pract Epidemiol Ment Health       Date:  2017-08-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.